Reviews Wellbutrin


No reviews yet.

Wellbutrin Drug Description
WELLBUTRIN®
(bupropion hydrochloride)
Tablets

WARNING Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening
and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN SR®,
and WELLBUTRIN XL® are not approved for smoking cessation treatment, but
bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin »




WELLBUTRIN (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1 propanone
hydrochloride. The molecular weight is 276.2. The empirical formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN is supplied for oral administration as 75-mg (yellow-gold) and 100-mg
(red) film-coated tablets. Each tablet contains the labeled amount of bupropion
hydrochloride and the inactive ingredients: 75-mg tablet – D&C Yellow No.
10 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl cellulose, hypromellose,
microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide;
100-mg tablet – FD&C Red No. 40 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl
cellulose, hypromellose, microcrystalline cellulose, polyethylene glycol, talc,
and titanium dioxide.
Last reviewed on RxList: 6/21/2010




Wellbutrin Drug Description
WELLBUTRIN®
(bupropion hydrochloride)
Tablets

WARNING Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening
and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN SR®,
and WELLBUTRIN XL® are not approved for smoking cessation treatment, but
bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin »




WELLBUTRIN (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1 propanone
hydrochloride. The molecular weight is 276.2. The empirical formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN is supplied for oral administration as 75-mg (yellow-gold) and 100-mg
(red) film-coated tablets. Each tablet contains the labeled amount of bupropion
hydrochloride and the inactive ingredients: 75-mg tablet – D&C Yellow No.
10 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl cellulose, hypromellose,
microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide;
100-mg tablet – FD&C Red No. 40 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl
cellulose, hypromellose, microcrystalline cellulose, polyethylene glycol, talc,
and titanium dioxide.
Last reviewed on RxList: 6/21/2010




Wellbutrin Drug Description
WELLBUTRIN®
(bupropion hydrochloride)
Tablets

WARNING Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening
and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN SR®,
and WELLBUTRIN XL® are not approved for smoking cessation treatment, but
bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin »




WELLBUTRIN (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1 propanone
hydrochloride. The molecular weight is 276.2. The empirical formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN is supplied for oral administration as 75-mg (yellow-gold) and 100-mg
(red) film-coated tablets. Each tablet contains the labeled amount of bupropion
hydrochloride and the inactive ingredients: 75-mg tablet – D&C Yellow No.
10 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl cellulose, hypromellose,
microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide;
100-mg tablet – FD&C Red No. 40 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl
cellulose, hypromellose, microcrystalline cellulose, polyethylene glycol, talc,
and titanium dioxide.
Last reviewed on RxList: 6/21/2010




Wellbutrin Drug Description
WELLBUTRIN®
(bupropion hydrochloride)
Tablets

WARNING Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening
and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN SR®,
and WELLBUTRIN XL® are not approved for smoking cessation treatment, but
bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin »




WELLBUTRIN (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1 propanone
hydrochloride. The molecular weight is 276.2. The empirical formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN is supplied for oral administration as 75-mg (yellow-gold) and 100-mg
(red) film-coated tablets. Each tablet contains the labeled amount of bupropion
hydrochloride and the inactive ingredients: 75-mg tablet – D&C Yellow No.
10 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl cellulose, hypromellose,
microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide;
100-mg tablet – FD&C Red No. 40 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl
cellulose, hypromellose, microcrystalline cellulose, polyethylene glycol, talc,
and titanium dioxide.
Last reviewed on RxList: 6/21/2010




Wellbutrin Drug Description
WELLBUTRIN®
(bupropion hydrochloride)
Tablets

WARNING Suicidality and Antidepressant Drugs
Use in Treating Psychiatric Disorders: Antidepressants increased the
risk compared to placebo of suicidal thinking and behavior (suicidality) in
children, adolescents, and young adults in short-term studies of major depressive
disorder (MDD) and other psychiatric disorders. Anyone considering the use of
WELLBUTRIN or any other antidepressant in a child, adolescent, or young adult
must balance this risk with the clinical need. Short-term studies did not show
an increase in the risk of suicidality with antidepressants compared to placebo
in adults beyond age 24; there was a reduction in risk with antidepressants
compared to placebo in adults aged 65 and older. Depression and certain other
psychiatric disorders are themselves associated with increases in the risk of
suicide. Patients of all ages who are started on antidepressant therapy should
be monitored appropriately and observed closely for clinical worsening, suicidality,
or unusual changes in behavior. Families and caregivers should be advised of
the need for close observation and communication with the prescriber. WELLBUTRIN
is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening
and Suicide Risk in Treating Psychiatric Disorders, PATIENT INFORMATION, and PRECAUTIONS: Pediatric Use.)
Use in Smoking Cessation Treatment: WELLBUTRIN®, WELLBUTRIN SR®,
and WELLBUTRIN XL® are not approved for smoking cessation treatment, but
bupropion under the name ZYBAN® is approved for this use. Serious neuropsychiatric
events, including but not limited to depression, suicidal ideation, suicide
attempt, and completed suicide have been reported in patients taking bupropion
for smoking cessation. Some cases may have been complicated by the symptoms
of nicotine withdrawal in patients who stopped smoking. Depressed mood may be
a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation,
has been reported in smokers undergoing a smoking cessation attempt without
medication. However, some of these symptoms have occurred in patients taking
bupropion who continued to smoke.
All patients being treated with bupropion for smoking cessation treatment should
be observed for neuropsychiatric symptoms including changes in behavior, hostility,
agitation, depressed mood, and suicide-related events, including ideation, behavior,
and attempted suicide. These symptoms, as well as worsening of pre-existing
psychiatric illness and completed suicide have been reported in some patients
attempting to quit smoking while taking ZYBAN in the postmarketing experience.
When symptoms were reported, most were during treatment with ZYBAN, but some
were following discontinuation of treatment with ZYBAN. These events have occurred
in patients with and without pre-existing psychiatric disease; some have experienced
worsening of their psychiatric illnesses. Patients with serious psychiatric
illness such as schizophrenia, bipolar disorder, and major depressive disorder
did not participate in the premarketing studies of ZYBAN.
Advise patients and caregivers that the patient using bupropion for smoking
cessation should stop taking bupropion and contact a healthcare provider immediately
if agitation, hostility, depressed mood, or changes in thinking or behavior
that are not typical for the patient are observed, or if the patient develops
suicidal ideation or suicidal behavior. In many postmarketing cases, resolution
of symptoms after discontinuation of ZYBAN was reported, although in some cases
the symptoms persisted; therefore, ongoing monitoring and supportive care should
be provided until symptoms resolve.
The risks of using bupropion for smoking cessation should be weighed against
the benefits of its use. ZYBAN has been demonstrated to increase the likelihood
of abstinence from smoking for as long as 6 months compared to treatment with
placebo. The health benefits of quitting smoking are immediate and substantial.
(See WARNINGS: Neuropsychiatric Symptoms and Suicide Risk in Smoking Cessation
Treatment and PATIENT INFORMATION.)

DRUG DESCRIPTION



What are the possible side effects of bupropion?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if...
Read All Potential Side Effects for Wellbutrin »




WELLBUTRIN (bupropion hydrochloride), an antidepressant of the aminoketone
class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin
re-uptake inhibitor, or other known antidepressant agents. Its structure closely
resembles that of diethylpropion; it is related to phenylethylamines. It is
designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1 propanone
hydrochloride. The molecular weight is 276.2. The empirical formula is C13H18ClNO•HCl.
Bupropion hydrochloride powder is white, crystalline, and highly soluble in
water. It has a bitter taste and produces the sensation of local anesthesia
on the oral mucosa. The structural formula is:








WELLBUTRIN is supplied for oral administration as 75-mg (yellow-gold) and 100-mg
(red) film-coated tablets. Each tablet contains the labeled amount of bupropion
hydrochloride and the inactive ingredients: 75-mg tablet – D&C Yellow No.
10 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl cellulose, hypromellose,
microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide;
100-mg tablet – FD&C Red No. 40 Lake, FD&C Yellow No. 6 Lake, hydroxypropyl
cellulose, hypromellose, microcrystalline cellulose, polyethylene glycol, talc,
and titanium dioxide.
Last reviewed on RxList: 6/21/2010





Other reviews about Wellbutrin on wordpress

FDA probe clears generic wellbutrin
  by missisyphus
from fiercepharma: 5. FDA probe clears generic Wellbutrin Comment | Forward to a friend Listen to all those generics makers heaving sighs of relief. The FDA has given the thumbs-up to […]


WELLBUTRIN (Bupropion, Zyban) - Side Effects and Withdrawal Symptoms
  by Your Friend
WELLBUTRIN - (Bupropion, Zyban) Side effects and Withdrawal Symptoms WELLBUTRIN is an atypical antidepressant. Bupropion, (generic name), is also prescribed as a smoking cessation medication, marketed as Zyban. Seizures […]


Wellbutrin, an update.
  by benny
Today marks day 5 of 90ish days on Wellbutrin. Wellbutrin, a very powerful antidepressant medication, doubles as a helper in smoking cessation. The major side effects: suicidal effects. Up […]


buy wellbutrin without prescription
  by 7ni7
Buy wellbutrin without prescription [caption id="attachment_12" align="aligncenter" width="313" caption="Buy wellbutrin without prescription"][/caption] We have the lowest prices on the goods! A system of cumulative discounts! We are waiting for you in our […]


Chantix and Zyban (Wellbutrin) to get black box warnings
  by giannakali
More black box warnings for an antidepressant (Wellbutrin) that doubles as a quit smoking drug (so it's also called Zyban) and Chantix the quit smoking drug with a […]


Wellbutrin, old friend
  by Gal Baby
The stress of the idiot stick figure with no soul, hubby, volunteer commitments and the never ending saga of the Phd have pushed me back into the familiar […]


Wellbutrin sr no prescription
  by eccecall
Wellbutrin sr no prescription Click Here: Wellbutrin sr no prescription Few of the highest paying, founded jointly by Shenyang, Pharmaceutical wellbutrin sr no prescription pharmacy premises, and […]


Wellbutrin gives me insomnia
  by Alice
Three months ago I told my friends I have depression and anxiety. The conversation went dead for a while, but they returned to normal conversation as if I […]


De-friending Wellbutrin
  by sciumi
I believe my tumultuous affair with Wellbutrin has come to an end. Last night I had a terrible, terrible crying fit after our cat bit me.  And, yeah, I […]


Caraco Markets Generic Wellbutrin
  by mnroush
Detroit-based Caraco Pharmaceutical Laboratories Ltd. (NYSE Amex: CPD) said Wednesday that it had started shipping bupropion hydrochloride extended release tablets. This product was recently approved by the United States […]



Other reviews about Wellbutrin on web:

Bupropion (also known as Wellbutrin, Zyban, Voxra, Budeprion, or Aplenzin; formerly known as amfebutamone) is an atypical antidepressant and smoking cessation aid. Bupropion - Wikipedia, the free encyclopedia


Wellbutrin (bupropion) is used to treat major depressive disorder and seasonal affective disorder. Includes Wellbutrin side effects, interactions and indications. Wellbutrin Information from Drugs.com


Welcome! This Web site is a resource for information about depression and WELLBUTRIN XL ®. It also offers helpful tools as well as access to e-mail alerts to help ... Once-Daily WELLBUTRIN XL®


Important Safety Information About Wellbutrin XL* Important Safety Information About Wellbutrin SR Important Safety Information About Wellbutrin Wellbutrin


Learn about the prescription medication Wellbutrin (Bupropion Hcl), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Wellbutrin (Bupropion Hcl) Drug Information: Uses, Side Effects ...


Accurate, FDA approved Wellbutrin information for healthcare professionals and patients - brought to you by Drugs.com. Wellbutrin Official FDA information, side effects and uses.


Find patient medical information for Wellbutrin Oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Wellbutrin Oral : Uses, Side Effects, Interactions, Pictures ...


Learn about Wellbutrin from the publishers of the Physicians Desk Reference. Find prescription drug information resources including interactions, side effects, symptoms ... Wellbutrin | Prescription Drug Information, Side Effects | PDRHealth


Wellbutrin withdrawal. There is a way to do Wellbutrin withdrawal without Wellbutrin withdrawal side effects. Wellbutrin withdrawal. Wellbutrin withdrawal. Wellbutrin withdrawal side effects ...


Wellbutrin side effects, dosage, and drug interactions. All accurate, up-to-date information is written for the consumer by healthcare professionals. Wellbutrin Oral Uses and How to Use





Featured Reviews

Reviews Ofloxacin Ophthalmic Solution

Ofloxacin Ophthalmic Solution Drug Description OFLOXACIN OPHTHALMIC SOLUTION USP, 0.3% DRUG DESCRIPTION Ofloxacin Ophthalmic Solution USP, 0.3% is a sterile ophthalmic solution. It is a fluorinated carboxyquinolone anti-infective for topical...
Read More  |  Review This
Reviews Infed

Infed Drug Description INFeD® (iron dextran) Injection USP WARNING THE PARENTERAL USE OF COMPLEXES OF IRON AND CARBOHYDRATES HAS RESULTED IN ANAPHYLACTIC-TYPE REACTIONS. DEATHS ASSOCIATED WITH SUCH ADMINISTRATION HAVE BEEN...
Read More  |  Review This
Reviews Lysteda

Lysteda Drug Description LYSTEDA (tranexamic acid) Tablets DRUG DESCRIPTION LYSTEDA is an antifibrinolytic drug. The chemical name is trans-4-Aminomethylcyclohexanecarboxylic acid. The structural formula is: ...
Read More  |  Review This
Reviews Lorabid

Lorabid Drug Description DRUG DESCRIPTION What are the possible side effects of loracarbef (Lorabid, Lorabid Pulvules)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing;...
Read More  |  Review This
Reviews Estradiol Vaginal Ring

Estring Drug Description ESTRING® (estradiol) Vaginal Ring WARNINGS ENDOMETRIAL CANCER Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....